Net sales and order backlog declined year-over-year, but cost reductions improved operating loss by 12%. Strategic partnerships, FDA collaboration, and new publications support future growth, though profitability and financing remain key risks.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.